**JPED-D-21-00387 – Supplementary Material**

**Supplementary Table 1** Characteristics of the 1,072 subjects who attended the study visit, stratified per age range.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Children and adolescents**  **(n = 342)** | **Adults**  **(n =730)** | **p** |
| Age in years - median (IQ) | 12 (10-15) | 49 (37-61) | < 0.01 |
| Female gender (%) | 146 (43) | 525 (72) | < 0.01 |
| Per capita family-income - median (IQ) | 160 (108-214) | 263 (170-413) | < 0.01 |
| N° of years at school - median (IQ) | 7 (4-9) | 11 (6-12) | < 0.01 |
| Comorbidities (%) | 1 (<1) | 282 (39) | < 0.01 |
| Inhaled budesonide or equivalent, mcg/day - median (IQ) | 400 (0-400) | 800 (500-1200) | < 0.01 |
| N° of subjects using long acting B2 agonist (%) | 77 (23) | 385 (53) | < 0.01 |
| ACQ score - median (IQ) | 0,8 (0,3-1,5) | 1,0 (0,3-2,0) | < 0.01 |
| FVC pre-BD, percent of predicted - median (IQ) | 111 (110-122) | 91 (80-102) | < 0.01 |
| FVC post-BD, percent of predicted - median (IQ) | 116 (105-126) | 94 (84-105) | < 0.01 |
| FEV1 pre-BD, percent of predicted - median (IQ) | 99 (90-113) | 84 (72-95) | < 0.01 |
| FEV1 post-BD, percent of predicted - median (IQ) | 108 (98-119) | 90 (78-102) | < 0.01 |
| FEV1/FVC ratio pre-BD, absolute value - median (IQ) | 83 (77-88) | 76 (70-81) | < 0.01 |
| FEV1/FVC ratio post-BD, absolute value - median (IQ) | 87 (81-91) | 78 (72-83) | < 0.01 |
| Total cost of asthma for the family, in USD - median (IQ) | 11 (2-29) | 9 (0-26) | 0.15 |
| Proportion of family income committed with asthma expenses - median (IQ) | 1.4 (0.2-5.6) | 1.1 (0.0-3.7) | 0.01 |

Financial values depicted in USD, inflated to June 2021.

**Supplementary Table 2** Binary logistic regression analyses to evaluate if markers of uncontrolled asthma would predict any asthma expense during the preceding thirty days.

|  |  |  |
| --- | --- | --- |
|  | OR (95 CI) | |
|  | Crude | Adjusteda |
| Reported any expense with asthma  Not taking inhaled corticosteroids maintenance therapy  Taking inhaled corticosteroids maintenance therapy | -  2.1 (1.3-3.4) | -  2.1 (1.3-3.4) |
| Reported any expense with asthma  ACQ ≥ 1,5  ACQ < 1,5 | -  2.9 (1.5-6.2) | -  3.1 (1.5-6.3) |
| Reported any expense with asthma  Absence of pre BD airway obstruction  Presence of pre BD airway obstruction | -  1.2 (0.7-1.9) | -  1.2 (0.7-1.9) |
| Reported any expense with asthma  Absence of post BD airway obstruction  Presence of post BD airway obstruction | -  3.3 (0.7-14.1) | -  3.2 (0.7-14.1) |

a Adjusted for the per capita family-income.